Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Keratosis, Actinic 2Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Keratosis 1Dermatitis, Contact 1Carcinoma 1

Interventions

Carboplatin 23Cisplatin 19pembrolizumab 14Paclitaxel 13Gemcitabine 12Pemetrexed 11130-nm albumin-bound paclitaxel 9Everolimus 8Cetuximab 8Fluorouracil 7Docetaxel 6Axitinib 6Albumin-Bound Paclitaxel 6osimertinib 5durvalumab 5Sunitinib 5Radiotherapy 5Nivolumab 5Erlotinib Hydrochloride 5Cyclophosphamide 5Sorafenib 4Radiation 4Irinotecan 4Ipilimumab 4vosaroxin 3Radiotherapy, Intensity-Modulated 3Octreotide 3Bevacizumab 31-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3trifluridine tipiracil drug combination 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma × Ointments × Clear all
NCT02587819 2016-04-14

Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment

Biosceptre

Phase 1 Completed
21 enrolled 9 charts
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡